
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Sotorasib, also known as Lumakras, is a targeted drug designed for patients with NSCLC carrying the KRAS G12C gene mutation. This medication inhibits the activity of the KRAS G12C ···【more】
Article source:Captain MedicineRelease date:2024-07-09Recommended:420
Sotorasibas a targeted therapeutic agent, is hailed as a milestone advancement in the medical field. As one of the pioneering small molecule inhibitors successfully targeting KRAS ···【more】
Article source:Captain MedicineRelease date:2024-07-09Recommended:402
Sotorasib is a targeted therapy for patients with advanced NSCLC with KRAS p.G12C mutations.KRAS geneis a key regulator during cell growth and division, when the p.G12C mutation oc···【more】
Article source:Captain MedicineRelease date:2024-07-09Recommended:459
Sotorasib represents a groundbreaking targeted therapy that has exhibited remarkable efficacy in combatting non-small cell lung cancer (NSCLC), particularly among individuals harbo···【more】
Article source:Captain MedicineRelease date:2024-07-09Recommended:405
Sotorasib, also known as AMG-510, is an orally bioavailable drug that falls under the category of selective KRAS G12C covalent inhibitors. By locking the KRAS G12C protein in an in···【more】
Article source:Captain MedicineRelease date:2024-07-09Recommended:478
Sotorasib emerges as a groundbreaking targeted therapy for non-small cell lung cancer (NSCLC) individuals carrying KRAS G12C alterations. Sotorasib exerts its therapeutic efficacy ···【more】
Article source:Captain MedicineRelease date:2024-07-09Recommended:381
Sotorasib, a small molecule inhibitor targeting the KRAS G12C gene mutation in non-small cell lung cancer (NSCLC), has garnered significant attention since its debut. Its distincti···【more】
Article source:Captain MedicineRelease date:2024-07-09Recommended:387
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:[list:visits]2024-09-07
In recent years, Laos has gradually become a major global supply source for generic drugs, leveragin···【more】
Recommended:[list:visits]2026-22-07
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies ···【more】
Recommended:[list:visits]2026-21-07
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was···【more】
Recommended:[list:visits]2026-20-07
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was···【more】
Recommended:[list:visits]2026-17-07
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos'···【more】
Recommended:[list:visits]2026-16-07
In recent years, Laos generic drugs have gradually come into view of oncology and chronic disease pa···【more】
Recommended:[list:visits]2026-15-07

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643